CN Bio
CN Bio is a leading organ-on-a-chip (OOC) company based in Cambridge, UK. CN Bio offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines.With more than a decade of experience in precision engineering and single and multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of advanced, predictive human organ models. The Company’s PhysioMimix® OOC range of microphysiological systems (MPS) bridges the relevance gap between traditional cell culture, in vivo animal studies, and human trials by advancing towards the simulation of human biological conditions. The technology provides deep mechanistic insights to enable researchers to refine preclinical study design, reducing the number of animals required, and better preparing and informing studies ahead of the clinic to support safe, efficacious and efficient therapeutic development.Content by CN Bio
| 2 min read
Two new animal microphysiological system models have been introduced to improve the translatability of preclinical drug safety assessments by enabling early, comparative evaluation of hepatotoxicity across human, rat, and dog Liver-on-a-chip models.
Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Available on Demand
Microphysiological systems offer a promising solution to the long-standing challenge of predicting clinical drug safety outcomes from preclinical models.
Discover how scalable, high-content liver-on-a-chip models improve drug safety evaluation in early development.
Explore advanced in vitro organ-on-a-chip models that improve drug safety assessment.
Available on Demand
Discover how researchers leverage microphysiological systems in toxicology studies.
| 5 min read
New modality drugs offer promising therapeutic approaches to address unmet medical needs – but not without challenges.
Available on Demand
Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety.
Page 1 of 1 - 9 Total Items
